General Biology and Medical Genetics Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Laboratory of Bioinformatics, Fondazione IRCCS Casa Sollievo della Sofferenza-Mendel, San Giovanni Rotondo (FG), Italy.
Mol Genet Genomic Med. 2022 Aug;10(8):e1972. doi: 10.1002/mgg3.1972. Epub 2022 May 27.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder, affecting 1:5000 individuals worldwide. All the genes associated to the disease (ENG, ACVRL1, SMAD4, GDF2) belong to the TGF-β/BMPs signaling pathway. We found 19 HHT unrelated families, coming from a Northern Italy region and sharing the ACVRL1 in-frame deletion c.289_294del (p.H97_N98).
To test the hypothesis of a founder effect, we analyzed 88 subjects from 19 families (66 variant carriers, showing clinical signs of HHT, and 22 non-carriers, unaffected) using eight microsatellite markers within 3.7 Mb around the ACVRL1 locus. After the haplotype reconstruction, age estimation of the variant was carried out.
We observed a common disease haplotype in 16/19 families, while three families showed evidence of recombination around the ACVRL1 locus. The subsequent age estimation analyses suggested that the mutation occurred about 8 generations ago, corresponding to about 200 years ago. We also present novel in silico and modeling data supporting the variant pathogenicity: the deletion alters the protein stability and removes the unique extracellular glycosylation site.
We have demonstrated, for the first time, a "founder effect" for a HHT pathogenic variant in Italy.
遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性血管疾病,影响全球每 5000 人中的 1 人。与该疾病相关的所有基因(ENG、ACVRL1、SMAD4、GDF2)均属于 TGF-β/BMPs 信号通路。我们发现了来自意大利北部地区的 19 个与 HHT 无关的家族,这些家族都携带有 ACVRL1 框内缺失 c.289_294del(p.H97_N98)。
为了验证存在 founder 效应的假设,我们使用 8 个微卫星标记分析了 19 个家族的 88 名受试者(66 名变异携带者,表现出 HHT 的临床症状,22 名非携带者,未受影响)。在构建单体型后,对变异的年龄进行了估计。
我们观察到 16/19 个家族存在共同的疾病单体型,而 3 个家族在 ACVRL1 基因座周围显示出重组的证据。随后的年龄估计分析表明,该突变发生在大约 8 代之前,约 200 年前。我们还提供了新的计算机模拟和建模数据,支持该变异的致病性:缺失改变了蛋白的稳定性并去除了独特的细胞外糖基化位点。
我们首次在意大利证明了 HHT 致病性变异存在“founder 效应”。